Table Info

Pathological/Molecular feature	Number of cases (%)
Histopathological Grade	Grade 2	2 (8.0)
Grade 3	23 (92.0)
CyclinD1	Negative	1(8.3)
Positive	11 (91.7)
Mib labelling Index	Mean (SD)	11.4 (9.1)
ZFTA fusion (L1CAM overexpression)	Negative	3 (37.5)
Positive	5 (62.5)
p53	Negative	6 (33.3)
Positive	12 (66.7)

Declarations

Author contributions

A Sahu and AV contributed equally to: Conceptualization, Data curation, Methodology, Investigation, Supervision,Writing—original draft, Writing—review & editing Formal analysis. A Snehil: Conceptualization, Data curation, Methodology, Writing—review & editing. A Sahay: Methodology, Formal analysis, Investigation. AM: Writing—review & editing, Investigation, Supervision. AJ: Supervision, Writing—review & editing. ES: Conceptualization, Methodology, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Approval was obtained from the ethics committee of Tata Memorial Hospital (Homi Bhabha National Institute), with ethical approval number 640/2020.

Consent to participate

Consent was exempted by ethical committee of Tata Memorial Hospital (Homi Bhabha National Institute).

Consent to publication

Consent was exempted by ethical committee of Tata Memorial Hospital (Homi Bhabha National Institute).

Availability of data and materials

The datasets for this manuscript are not publicly available because data contains personally identifiable information that may be restricted from public access to protect individuals’ privacy.

Funding

Not applicable.

Copyright

References

Marks JE, Adler SJ. A comparative study of ependymomas by site of origin. Int J Radiat Oncol Biol Phys. 1982;8:37–43. [DOI] [PubMed]

Chamberlain MC. Ependymomas. Curr Neurol Neurosci Rep. 2003;3:193–9. [DOI] [PubMed]

Amirian ES, Armstrong TS, Gilbert MR, Scheurer ME. Predictors of survival among older adults with ependymoma. J Neurooncol. 2012;107:183–9. [DOI] [PubMed] [PMC]

Metellus P, Barrie M, Figarella-Branger D, Chinot O, Giorgi R, Gouvernet J, et al. Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain. 2007;130:1338–49. [DOI] [PubMed]

Barone BM, Elvidge AR. Ependymomas: a clinical survey. J Neurosurg. 1970;33:428–38. [DOI] [PubMed]

Coulon RA, Till K. Intracranial ependymomas in children: a review of 43 cases. Childs Brain. 1977;3:154–68. [PubMed]

Mork SJ, Loken AC. Ependymoma. A follow-up study of 101 cases. Cancer. 1977;40:907–15. [DOI] [PubMed]

Swartz JD, Zimmerman RA, Bilaniuk LT. Computed tomography of intracranial ependymomas. Radiology. 1982;143:97–101. [DOI] [PubMed]

WHO Classification of Tumours Editorial Boardet. Supratentorial ependymoma. Central Nervous System Tumours. Lyon (France): International Agency for Research on Cancer; 2021. pp. 161–168.

10.

Shuangshoti S, Rushing EJ, Mena H, Olsen C, Sandberg GD. Supratentorial extraventricular ependymal neoplasms. Cancer. 2005;103:2598–605. [DOI] [PubMed]

11.

Mermuys K, Jeuris W, Vanhoenacker PK, Van Hoe L, D’Haenens P. Supratentorial ependymoma. Radiographics. 2005;25:486–90. [DOI]

12.

Bunyaratavej K, Shuangshoti S, Tanboon J, Chantra K, Khaoroptham S. Supratentorial lobar anaplastic ependymoma resembling cerebral metastasis: a case report. J Med Assoc Thai. 2004;87:829–33. [PubMed]

13.

Guyotat J, Signorelli F, Desme S, Frappaz D, Madarassy G, Montange MF, et al. Intracranial ependymomas in adult patients: analyses of prognostic factors. J Neurooncol. 2002;60:255–68. [DOI] [PubMed]

14.

Sayegh ET, Aranda D, Kim JM, Oh T, Parsa AT, Oh MC. Prognosis by tumor location in adults with intracranial ependymomas. J Clin Neurosci. 2014;21:2096–101. [DOI] [PubMed] [PMC]

15.

Rodríguez D, Cheung MC, Housri N, Quinones-Hinojosa A, Camphausen K, Koniaris LG. Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973–2005). J Surg Res. 2009;156:340–51. [DOI] [PubMed] [PMC]

16.

Winn HR, Youmans JR. Youmans Neurological Surgery. 5th ed. Philadelphia: Elsevier-Health Sciences Division; 2004.

17.

Nowak J, Jünger ST, Huflage H, Seidel C, Hohm A, Vandergrift LA, et al. MRI phenotype of RELA-fused pediatric supratentorial ependymoma. Clinical Neuroradiology. 2019;29:595–604. [DOI] [PubMed]

18.

McLaughlin MP, Marcus RB Jr, Buatti JM, McCollough WM, Mickle JP, Kedar A, et al. Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys. 1998;40:845–50. [DOI] [PubMed]

19.

Metellus P, Guyotat J, Chinot O, Durand A, Barrie M, Giorgi R, et al. Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. Neuro Oncol. 2010;12:976–84. [DOI] [PubMed] [PMC]

20.

Reni M, Brandes AA, Vavassori V, Cavallo G, Casagrande F, Vastola F, et al. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer. 2004;100:1221–9. [DOI] [PubMed]

21.

Schild SE, Nisi K, Scheithauer BW, Wong WW, Lyons MK, Schomberg PJ, et al. The results of radiotherapy for ependymomas: the mayo clinic experience. Int J Radiat Oncol Biol Phys. 1998;42:953–8. [DOI] [PubMed]

22.

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231–51. [DOI] [PubMed] [PMC]

23.

Niazi TN, Jensen EM, Jensen RL. WHO grade II and III supratentorial hemispheric ependymomas in adults: case series and review of treatment options. J Neurooncol. 2009;91:323–8. [DOI] [PubMed]

24.

Metellus P, Figarella-Branger D, Guyotat J, Barrie M, Giorgi R, Jouvet A, et al. Supratentorial ependymomas: prognostic factors and outcome analysis in a retrospective series of 46 adult patients. Cancer. 2008;113:175–85. [DOI] [PubMed]

25.

Mangalore S, Aryan S, Prasad C, Santosh V. Imaging characteristics of supratentorial ependymomas: study on a large single institutional cohort with histopathological correlation. Asian J Neurosurg. 2015;10:276–81. [DOI] [PubMed] [PMC]

26.

Furie DM, Provenzale JM. Supratentorial ependymomas and subependymomas: CT and MR appearance. J Comput Assist Tomogr. 1995;19:518–26. [DOI] [PubMed]

27.

Yuh EL, Barkovich AJ, Gupta N. Imaging of ependymomas: MRI and CT. Childs Nerv Syst. 2009;25:1203–13. [DOI] [PubMed] [PMC]

28.

Hanakita J, Handa H. Clinical features and CT scan findings of supratentorial ependymomas and ependymoblastomas. No Shinkei Geka. 1984;12:253–60. [PubMed]

29.

Au Yong KJ, Jaremko JL, Jans L, Bhargava R, Coleman LT, Mehta V, et al. How specific is the MRI appearance of supratentorial atypical teratoid rhabdoid tumors? Pediatr Radiol. 2013;43:347–54. [DOI] [PubMed]

30.

Dangouloff-Ros V, Tauziède-Espariat A, Roux CJ, Levy R, Grévent D, Brunelle F, et al. CT and multimodal MR imaging features of embryonal tumors with multilayered rosettes in children. AJNR Am J Neuroradiol. 2019;40:732–6. [PubMed] [PMC]

31.

Ernestus RI, Wilcke O, Schröder R. Supratentorial ependymomas in childhood: clinicopathological findings and prognosis. Acta Neurochir (Wien). 1991;111:96–102. [DOI] [PubMed]